Diphtheria Drug Development Pipeline Study, H2 2018
Diphtheria Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Diphtheria pipeline products.
DISEASE OVERVIEW
Global Diphtheria market is estimated to be around $4.5 billion in 2020 driven by the US spending. 16 companies are currently active in development of vaccines and treatment options for Diphtheria worldwide. 21 therapeutic candidates are in various stages of pre-clinical/ discovery or clinical trials (phase 1, phase 2, phase 3) stages.
Diphtheria is one of the key areas of focus among infectious disease pipeline. Diphtheria is caused by Corynebacterium diphtheria, which produce exotoxins and the primary areas infected in humans are throat and upper airways.
Typical symptoms extend from sore throat, mild fever together with swollen glands inside throat in mild cases. In serious conditions, it can result in myocarditis or peripheral neuropathy.
Despite wide administration of vaccines (bacterial toxoid) against Diphtheria in most countries, children in low income countries continue to be largely affected. Currently, 16 companies are actively participating in developing vaccines and cure for Diphtheria worldwide. The Diphtheria pipeline companies include%li%Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Boryung Pharmaceutical Co Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma%li%Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi SA, Serum Institute of India Ltd, Shantha Biotechnics Pvt Ltd, Tianjin CanSino Biotechnology Inc and Wockhardt Ltd.
REPORT DESCRIPTION
The Diphtheria pipeline guide presents complete overview of drugs currently being developed for Diphtheria. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Diphtheria pipeline candidate.
Research and Development progress along with latest news related to each of the Diphtheria pipeline candidates is included.
Major companies participating in therapeutic development of Diphtheria are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Diphtheria from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Diphtheria clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Diphtheria pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF DIPHTHERIA PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Global Diphtheria market is estimated to be around $4.5 billion in 2020 driven by the US spending. 16 companies are currently active in development of vaccines and treatment options for Diphtheria worldwide. 21 therapeutic candidates are in various stages of pre-clinical/ discovery or clinical trials (phase 1, phase 2, phase 3) stages.
Diphtheria is one of the key areas of focus among infectious disease pipeline. Diphtheria is caused by Corynebacterium diphtheria, which produce exotoxins and the primary areas infected in humans are throat and upper airways.
Typical symptoms extend from sore throat, mild fever together with swollen glands inside throat in mild cases. In serious conditions, it can result in myocarditis or peripheral neuropathy.
Despite wide administration of vaccines (bacterial toxoid) against Diphtheria in most countries, children in low income countries continue to be largely affected. Currently, 16 companies are actively participating in developing vaccines and cure for Diphtheria worldwide. The Diphtheria pipeline companies include%li%Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Boryung Pharmaceutical Co Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma%li%Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi SA, Serum Institute of India Ltd, Shantha Biotechnics Pvt Ltd, Tianjin CanSino Biotechnology Inc and Wockhardt Ltd.
REPORT DESCRIPTION
The Diphtheria pipeline guide presents complete overview of drugs currently being developed for Diphtheria. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Diphtheria pipeline candidate.
Research and Development progress along with latest news related to each of the Diphtheria pipeline candidates is included.
Major companies participating in therapeutic development of Diphtheria are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Diphtheria from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Diphtheria clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Diphtheria pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF DIPHTHERIA PIPELINE REPORT INCLUDES
- Panorama of Diphtheria pipeline markets including statistics on therapeutic drugs and companies involved
- Diphtheria Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Diphtheria pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Diphtheria pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Diphtheria pipeline therapeutics
- Get clear understanding of the entire Diphtheria pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Diphtheria pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Diphtheria Pipeline include-
Number of Companies with Diphtheria projects in pre-clinical Development-
Number of Companies with Diphtheria projects in Clinical Development-
Diphtheria Pipeline Companies based in Americas
Diphtheria Pipeline Companies based in Europe
Diphtheria Pipeline Companies based in Asia Pacific
Diphtheria Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Diphtheria Pipeline Agents in pre- clinical/Discovery stage of Development
Diphtheria Pipeline Agents in Clinical Development stage
Diphtheria Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Diphtheria Pipeline agents
II. INSIGHTS INTO DIPHTHERIA PIPELINE
1. Disease Overview
Introduction to Diphtheria
Symptoms and Causes of Diphtheria
Treatment or Prevention Options for Diphtheria
Other Details
2. Phase wise Pipeline Compounds
Diphtheria Pipeline- Pre- Clinical/Discovery stage Drugs
Diphtheria Pipeline- Phase 1 stage Drugs
Diphtheria Pipeline- Phase 2 stage Drugs
Diphtheria Pipeline- Phase 3 stage Drugs
Diphtheria Pipeline- Pre-Registration stage Drugs
3. Company wise Diphtheria Pipeline Compounds
4. Diphtheria Pipeline by Mechanism of Action
III. DIPHTHERIA PIPELINE COMPOUND DETAILS
DTaP-IPV-Hib Vaccine
DTaP-Hib vaccine
DTcP vaccine
BK1310
(BVN-002, DTaP-IPV) combination vaccine
Diphtheria, Tetanus and Pertussis (Whole Cell) Vaccine
VN-0105
GC3111A
(diphtheria, tetanus, acellular pertussis, hepatitis B recombinent, poliomyelitis, haemophilus influenza type B) vaccine
DPT-H-HiB pentavalent vaccine
LBVD vaccine
s315
Adsorbed Acellular Pertussis (tricomponent) vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
(Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b, Polio) vaccine
Adacel+ Tdap booster
(DTP-HepB-Polio-Hib) Pediatric hexavalent vaccine
DTaP Vaccine
DTwP-HepB-Hib-IPV vaccine
DTcP vaccine
vaccine for Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b in Indian children
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. DIPHTHERIA PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
BIKEN Corporation
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Company
GC Pharma- Korea
GlaxoSmithKline Plc
Indian Immunologicals Ltd
LG Chem Limited
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi SA
Sanofi Pasteur SA
Serum Institute of India
Shantha Biotechnics Pvt Ltd
Tianjin CanSino Biotechnology Inc
Wockhardt Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL DIPHTHERIA PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Diphtheria Pipeline include-
Number of Companies with Diphtheria projects in pre-clinical Development-
Number of Companies with Diphtheria projects in Clinical Development-
Diphtheria Pipeline Companies based in Americas
Diphtheria Pipeline Companies based in Europe
Diphtheria Pipeline Companies based in Asia Pacific
Diphtheria Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Diphtheria Pipeline Agents in pre- clinical/Discovery stage of Development
Diphtheria Pipeline Agents in Clinical Development stage
Diphtheria Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Diphtheria Pipeline agents
II. INSIGHTS INTO DIPHTHERIA PIPELINE
1. Disease Overview
Introduction to Diphtheria
Symptoms and Causes of Diphtheria
Treatment or Prevention Options for Diphtheria
Other Details
2. Phase wise Pipeline Compounds
Diphtheria Pipeline- Pre- Clinical/Discovery stage Drugs
Diphtheria Pipeline- Phase 1 stage Drugs
Diphtheria Pipeline- Phase 2 stage Drugs
Diphtheria Pipeline- Phase 3 stage Drugs
Diphtheria Pipeline- Pre-Registration stage Drugs
3. Company wise Diphtheria Pipeline Compounds
4. Diphtheria Pipeline by Mechanism of Action
III. DIPHTHERIA PIPELINE COMPOUND DETAILS
DTaP-IPV-Hib Vaccine
DTaP-Hib vaccine
DTcP vaccine
BK1310
(BVN-002, DTaP-IPV) combination vaccine
Diphtheria, Tetanus and Pertussis (Whole Cell) Vaccine
VN-0105
GC3111A
(diphtheria, tetanus, acellular pertussis, hepatitis B recombinent, poliomyelitis, haemophilus influenza type B) vaccine
DPT-H-HiB pentavalent vaccine
LBVD vaccine
s315
Adsorbed Acellular Pertussis (tricomponent) vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
(Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b, Polio) vaccine
Adacel+ Tdap booster
(DTP-HepB-Polio-Hib) Pediatric hexavalent vaccine
DTaP Vaccine
DTwP-HepB-Hib-IPV vaccine
DTcP vaccine
vaccine for Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b in Indian children
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. DIPHTHERIA PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
BIKEN Corporation
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Company
GC Pharma- Korea
GlaxoSmithKline Plc
Indian Immunologicals Ltd
LG Chem Limited
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi SA
Sanofi Pasteur SA
Serum Institute of India
Shantha Biotechnics Pvt Ltd
Tianjin CanSino Biotechnology Inc
Wockhardt Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL DIPHTHERIA PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
